Drug Type Small molecule drug |
Synonyms PERA 5720, PERA5720 |
Target |
Action modulators |
Mechanism 17β-HSD5 modulators(Aldo-keto-reductase family 1 member C3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Polyendocrine Metabolic Ovarian Syndrome | Preclinical | United States | 01 Jul 2026 |





